Atrys Health (ATRY) Q2 2024 earnings summary

Executive summary

• Achieved €107.4 million in revenue and €25.3 million in adjusted EBITDA for H1 2024, confirming strong organic growth and margin improvement, with all core business lines—prevention, diagnosis, and oncology—showing positive trends.

• Growth driven by operational efficiencies, automation, and AI, with a focus on expanding services in Latin America and Europe, and new strategic alliances with Bupa and Banmédica.

• Guidance for 2024 reaffirmed: targeting €220 million in revenue and exceeding €47 million in adjusted EBITDA.

Financial highlights

• Revenue grew 5% year-over-year to €107.4 million; at constant currency, growth would be 6.4%.

• Adjusted EBITDA increased 24.6% to €25.2 million, with margin up 368 basis points year-over-year.

• Gross margin reached 67.2%, down 146 basis points due to service mix shift toward precision medicine.

• Net loss reduced to €16.6 million from €23 million in H1 2023, mainly due to non-cash extraordinary items.

• Operating cash flow grew over 40% year-over-year; CapEx reduced by 12% to €6 million.

Outlook and guidance

• 2024 revenue expected to reach €220 million, with adjusted EBITDA to surpass €47 million.

• Free cash flow for the year projected to be at equilibrium or slightly positive.

• Net profit expected to break even in 2025 as extraordinary impacts subside.